{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:15:32Z","timestamp":1792883732934,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01434-2","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:44:30Z","timestamp":1767851070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["First-line treatment for CLL in the era of targeted therapy"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-9296","authenticated-orcid":false,"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"1434_CR1","unstructured":"Wendtner C-M, Al-Sawaf O, Binder M, Dreger P, Eichhorst B, Gregor M, et al. Onkopedia Guidelines: Chronic lymphocytic leukemia (CLL). (Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie (DGHO), \u00d6sterreichische Gesellschaft f\u00fcr H\u00e4matologie undOnkologie (OeGHO), Schweizerische Gesellschaft f\u00fcr H\u00e4matologie (SGH+SSH), and Schweizerische Gesellschaft f\u00fcr MedizinischeOnkologie (SGMO), 2024). https:\/\/www.onkopedia.com\/de\/onkopedia\/archive\/guidelines\/chronische-lymphatische-leukaemie-cll\/version-30092025T131113\/@@guideline\/html\/index.html. Accessed 28 Aug 2025."},{"key":"1434_CR2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma V.1.2026 (National Comprehensive Cancer Network (NCCN), 2025). NCCN.org. Accessed 28 Aug 2025."},{"key":"1434_CR3","unstructured":"Aurran T, Bussot L, de Guibert S, Dilhuydy M-S, Feugier P, Fornecker L-M, et al. Recommandations de prise en charge de la leucemie lymphoide chronique actualisation des algorithmes de traitement (French Innovative Leukemia Organization (FILO), 2023)."},{"key":"1434_CR4","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440\u201350.","journal-title":"Blood Adv"},{"key":"1434_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","volume":"107","author":"C Moreno","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107:2108\u201320.","journal-title":"Haematologica"},{"key":"1434_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","volume":"36","author":"JP Sharman","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia. 2022;36:1171\u20135.","journal-title":"Leukemia"},{"key":"1434_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031\u201343.","journal-title":"Lancet Oncol"},{"key":"1434_CR8","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517\u201328.","journal-title":"N Engl J Med"},{"key":"1434_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112\u201320.","journal-title":"Blood"},{"key":"1434_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535\u201352.","journal-title":"Lancet Oncol"},{"key":"1434_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37648-w","volume":"14","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14:2147.","journal-title":"Nat Commun"},{"key":"1434_CR12","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853\u201365.","journal-title":"J Clin Oncol"},{"key":"1434_CR13","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:EVIDoa2200006.","journal-title":"NEJM Evid"},{"key":"1434_CR14","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3324\/haematol.2018.208603","volume":"104","author":"M Furstenau","year":"2019","unstructured":"Furstenau M, Hallek M, Eichhorst B. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019;104:2144\u201354.","journal-title":"Haematologica"},{"key":"1434_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23\u201333.","journal-title":"Ann Oncol"},{"key":"1434_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00756-9","volume":"12","author":"PJ Hampel","year":"2022","unstructured":"Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022;12:161.","journal-title":"Blood Cancer J"},{"key":"1434_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/hematology.2024000656","volume":"2024","author":"E Tausch","year":"2024","unstructured":"Tausch E, Schneider C, Stilgenbauer S. Risk-stratification in frontline CLL therapy: standard of care. Hematology Am Soc Hematol Educ Program. 2024;2024:457\u201366.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1434_CR18","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/blood.2019004492","volume":"135","author":"E Tausch","year":"2020","unstructured":"Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135:2402\u201312.","journal-title":"Blood"},{"key":"1434_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/11587650-000000000-00000","volume":"28","author":"V Goede","year":"2011","unstructured":"Goede V, Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. Drugs Aging. 2011;28:163\u201376.","journal-title":"Drugs Aging"},{"key":"1434_CR20","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","volume":"9","author":"JD Soumerai","year":"2025","unstructured":"Soumerai JD, Barrientos J, Ahn I, Coombs C, Gladstone D, Hoffman M, et al. Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Adv. 2025;9:1213\u201329.","journal-title":"Blood Adv"},{"key":"1434_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/hematology.2021000234","volume":"2021","author":"HR Shah","year":"2021","unstructured":"Shah HR, Stephens DM. Is there a role for anti-CD20 antibodies in CLL? Hematology Am Soc Hematol Educ Program. 2021;2021:68\u201375.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1434_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1182\/blood-2021-153146","volume":"138","author":"JA Woyach","year":"2021","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Blood. 2021;138:639.","journal-title":"Blood"},{"key":"1434_CR23","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood.2024028205","volume":"146","author":"JA Burger","year":"2025","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Tedeschi A, Sarma A, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL. Blood. 2025;146:2168\u201376.","journal-title":"Blood"},{"key":"1434_CR24","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","volume":"26","author":"JC Byrd","year":"2020","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, et al. Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study. Clin Cancer Res. 2020;26:3918\u201327.","journal-title":"Clin Cancer Res"},{"key":"1434_CR25","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","volume":"17","author":"S O\u2019Brien","year":"2016","unstructured":"O\u2019Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409\u201318.","journal-title":"Lancet Oncol"},{"key":"1434_CR26","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1200\/JCO.2025.43.16_suppl.7011","volume":"43","author":"CSL Tam","year":"2025","unstructured":"Tam CSL, Ghia P, Shadman M, Munir T, Opat S, Walker P, et al. SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). J Clin Oncol. 2025;43:7011.","journal-title":"J Clin Oncol"},{"key":"1434_CR27","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1080\/10428194.2021.2020779","volume":"63","author":"JA Burger","year":"2022","unstructured":"Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, et al. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022;63:1375\u201386.","journal-title":"Leuk Lymphoma"},{"key":"1434_CR28","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1182\/blood.2023021959","volume":"143","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Perez Burbano G, Ruppert AS, Miller C, Heerema NA, Zhao W, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143:1616\u201327.","journal-title":"Blood"},{"key":"1434_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1056\/NEJMc2005943","volume":"383","author":"IE Ahn","year":"2020","unstructured":"Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med. 2020;383:498\u2013500.","journal-title":"N Engl J Med"},{"key":"1434_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1182\/blood.2024024476","volume":"146","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik AP, Patel K, Flinn IW, et al. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025;146:1276\u201385.","journal-title":"Blood"},{"key":"1434_CR31","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO-24-02265","volume":"43","author":"M Shadman","year":"2024","unstructured":"Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u2039ve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2024;43:780\u20137.","journal-title":"J Clin Oncol"},{"key":"1434_CR32","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924\u201335.","journal-title":"Blood"},{"key":"1434_CR33","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol"},{"key":"1434_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"1434_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107016","volume":"125","author":"C Owen","year":"2023","unstructured":"Owen C, Banerji V, Johnson N, Gerrie A, Aw A, Chen C, et al. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leuk Res. 2023;125:107016.","journal-title":"Leuk Res"},{"key":"1434_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107372","volume":"133","author":"C Owen","year":"2023","unstructured":"Owen C, Eisinga S, Banerji V, Johnson N, Gerrie AS, Aw A, et al. Canadian evidence-based guideline for treatment of relapsed\/refractory chronic lymphocytic leukemia. Leuk Res. 2023;133:107372.","journal-title":"Leuk Res"},{"key":"1434_CR37","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"JR Brown","year":"2024","unstructured":"Brown JR, Eichhorst B, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood. 2024;144:2706\u201317.","journal-title":"Blood"},{"key":"1434_CR38","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874\u20139.","journal-title":"Haematologica"},{"key":"1434_CR39","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1182\/bloodadvances.2024015493","volume":"9","author":"M Shadman","year":"2025","unstructured":"Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, et al. Zanubrutinib is well tolerated and effective in patients with CLL\/SLL intolerant of ibrutinib\/acalabrutinib: updated results. Blood Adv. 2025;9:4100\u201310.","journal-title":"Blood Adv"},{"key":"1434_CR40","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","volume":"106","author":"KA Rogers","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica. 2021;106:2364\u201373.","journal-title":"Haematologica"},{"key":"1434_CR41","doi-asserted-by":"publisher","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","volume":"6","author":"F Baptiste","year":"2019","unstructured":"Baptiste F, Cautela J, Ancedy Y, Resseguier N, Aurran T, Farnault L, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6:e001049.","journal-title":"Open Heart"},{"key":"1434_CR42","doi-asserted-by":"publisher","first-page":"e47546cf","DOI":"10.1097\/01.HS9.0000969432.47546.cf","volume":"7","author":"S Hwang","year":"2023","unstructured":"Hwang S, Wang J, Tian Z, Qi X, Jiang Y, Zhang S, et al. P632: Comparison of treatment-emergent adverse events of acalabrutinib and zanubrutinib in clinical trials in B-cell malignancies: a systematic review and meta-analysis. HemaSphere. 2023;7:e47546cf.","journal-title":"HemaSphere"},{"key":"1434_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104428","volume":"201","author":"A Sto\u017cek-Tutro","year":"2024","unstructured":"Sto\u017cek-Tutro A, Reczek M, Kawalec P. Safety profile of first-line targeted therapies in elderly and\/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2024;201:104428.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1434_CR44","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"1434_CR45","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739\u201354.","journal-title":"N Engl J Med"},{"key":"1434_CR46","doi-asserted-by":"crossref","unstructured":"F\u00fcrstenau M, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, et al. The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: final analysis from the phase 3 GAIA\/CLL13 trial. EHA 2025, Milan, Italy.","DOI":"10.1002\/hon.70093_70"},{"key":"1434_CR47","doi-asserted-by":"publisher","first-page":"400","DOI":"10.6004\/jadpro.2022.13.4.4","volume":"13","author":"M Waggoner","year":"2022","unstructured":"Waggoner M, Katsetos J, Thomas E, Galinsky I, Fox H. Practical management of the venetoclax-treated patient in chronic lymphocytic leukemia and acute myeloid leukemia. J Adv Pract Oncol. 2022;13:400\u201315.","journal-title":"J Adv Pract Oncol"},{"key":"1434_CR48","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1182\/blood-2019-126570","volume":"134","author":"O Al-Sawaf","year":"2019","unstructured":"Al-Sawaf O, Fink A-M, Robrecht S, Sinha A, Tandon M, Eichhorst BF, et al. Prevention and management of tumor lysis syndrome in patients with CLL and coexisting conditions treated with venetoclax-obinutuzumab or chlorambucil-obinutuzumab: results from the randomized CLL14 trial. Blood. 2019;134:4315.","journal-title":"Blood"},{"key":"1434_CR49","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa2310063","volume":"390","author":"T Munir","year":"2024","unstructured":"Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390:326\u201337.","journal-title":"N Engl J Med"},{"key":"1434_CR50","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood-2023-177713","volume":"142","author":"C Moreno","year":"2023","unstructured":"Moreno C, Munir T, Owen C, Follows G, Hernandez Rivas J-A, Benjamini O, et al. First-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the GLOW study. Blood. 2023;142:634.","journal-title":"Blood"},{"key":"1434_CR51","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139:3278\u201389.","journal-title":"Blood"},{"key":"1434_CR52","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","volume":"7","author":"N Jain","year":"2021","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7:1213\u20139.","journal-title":"JAMA Oncol"},{"key":"1434_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/01.HS9.0000843472.57904.29","volume":"6","author":"P Hillmen","year":"2022","unstructured":"Hillmen P, Pitchford A, Bloor A, Pettitt A, Patten P, Forconi F, et al. S145: The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial. HemaSphere. 2022;6:46\u20137.","journal-title":"HemaSphere"},{"key":"1434_CR54","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2024-203269","volume":"144","author":"CU Niemann","year":"2024","unstructured":"Niemann CU, Munir T, Owen C, Follows G, Hernandez Rivas J-A, Benjamini O, et al. First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): GLOW study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis. Blood. 2024;144:1871.","journal-title":"Blood"},{"key":"1434_CR55","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1200\/JCO.2025.43.16_suppl.7036","volume":"43","author":"P Ghia","year":"2025","unstructured":"Ghia P, Barr PM, Allan JN, Siddiqi T, Tedeschi A, Kipps TJ, et al. Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. J Clin Oncol. 2025;43:7036.","journal-title":"J Clin Oncol"},{"key":"1434_CR56","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa2504341","volume":"393","author":"T Munir","year":"2025","unstructured":"Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, et al. Measurable residual disease-guided therapy for chronic lymphocytic leukemia. N Engl J Med. 2025;393:1177\u201390.","journal-title":"N Engl J Med"},{"key":"1434_CR57","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJMoa2409804","volume":"392","author":"JR Brown","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392:748\u201362.","journal-title":"N Engl J Med"},{"key":"1434_CR58","unstructured":"ClinicalTrials.gov. Study of acalabrutinib (ACP-196) in combination with venetoclax (ABT-199), with and without obinutuzumab (GA101) versus chemoimmunotherapy for previously untreated CLL (AMPLIFY). 2024. https:\/\/clinicaltrials.gov\/study\/NCT03836261. Accessed 18 Jun 2024."},{"key":"1434_CR59","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1200\/JCO-24-02503","volume":"43","author":"MS Davids","year":"2025","unstructured":"Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, et al. Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol. 2025;43:788\u201399.","journal-title":"J Clin Oncol"},{"key":"1434_CR60","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1182\/blood.2023020158","volume":"142","author":"PA Thompson","year":"2023","unstructured":"Thompson PA, Bazinet A, Wierda WG, Tam CS, O\u2019Brien SM, Saha S, et al. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood. 2023;142:1784\u20138.","journal-title":"Blood"},{"key":"1434_CR61","unstructured":"ClinicalTrials.gov. Ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukaemia (CLL) (CLL17). 2024. https:\/\/clinicaltrials.gov\/study\/NCT04608318. Accessed 18 Jun 2024."},{"key":"1434_CR62","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.2217\/fon-2022-0456","volume":"18","author":"CE Ryan","year":"2022","unstructured":"Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, et al. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022;18:3689\u201399.","journal-title":"Future Oncol"},{"key":"1434_CR63","unstructured":"ClinicalTrials.gov. Study of sonrotoclax (BGB-11417) plus zanubrutinib (BGB-3111) compared with venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06073821. Accessed 9 Jul 2024."},{"key":"1434_CR64","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/blood-2023-179541","volume":"142","author":"CS Tam","year":"2023","unstructured":"Tam CS, Anderson MA, Lasica M, Verner E, Opat SS, Ma S. et al. Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-na\u2039ve chronic lymphocytic leukemia\/small lymphocytic lymphoma (TN-CLL\/SLL): data from an ongoing phase 1\/2 study. Blood. 2023;142:327","journal-title":"Blood"},{"key":"1434_CR65","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1182\/blood-2024-199175","volume":"144","author":"JD Soumerai","year":"2024","unstructured":"Soumerai JD, Cheah CY, Anderson MA, Lasica M, Verner E, Opat SS. Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1\/1b study BGB-11417-101. Blood. 2024;144:1012","journal-title":"Blood"},{"key":"1434_CR66","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1200\/JCO-25-00758","volume":"43","author":"M Shadman","year":"2025","unstructured":"Shadman M, Munir T, Ma S, Lasica M, Tani M, Robak T, et al. Zanubrutinib and venetoclax for patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA arm D results. J Clin Oncol. 2025;43:2409\u201317.","journal-title":"J Clin Oncol"},{"key":"1434_CR67","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","volume":"8","author":"JD Soumerai","year":"2021","unstructured":"Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021;8:e879\u201390.","journal-title":"Lancet Haematol"},{"key":"1434_CR68","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1182\/blood-2024-205697","volume":"144","author":"JD Soumerai","year":"2024","unstructured":"Soumerai JD, Dogan A, Seshan V, Flaherty KL, Slupe N, Carter J, et al. Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-na\u00efve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (\u0394MRD400). Blood. 2024;144:1867.","journal-title":"Blood"},{"key":"1434_CR69","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1182\/blood-2023-174465","volume":"142","author":"JN Allan","year":"2023","unstructured":"Allan JN, Helbig D, Mulvey E, Nazir S, Stewart S, Lapinta ML, et al. Zanubrutinib and venetoclax as initial therapy for CLL\/SLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG). Blood. 2023;142:3285.","journal-title":"Blood"},{"key":"1434_CR70","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787\u201398.","journal-title":"Leukemia"},{"key":"1434_CR71","unstructured":"Munir T, Girvan S, Cairns D, Bloor A, Allsup D, Varghese A, et al. Ibrutinib plus venetoclax with MRD-guided duration of treatment is superior to both continuous ibrutinib monotherapy and FCR for previously untreated CLL: report of the phase III UK FLAIR study. EHA 2025, Milan, Italy."},{"key":"1434_CR72","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1182\/blood-2023-189711","volume":"142","author":"N Jain","year":"2023","unstructured":"Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, et al. Combined ibrutinib and venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL): 5-year follow-up data. Blood. 2023;142:4635\u20139.","journal-title":"Blood"},{"key":"1434_CR73","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095\u2013103.","journal-title":"N Engl J Med"},{"key":"1434_CR74","unstructured":"Genentech USA, Inc. VENCLEXTA (venetoclax tablets), for oral use \u2013 US prescribing information. Genentech USA, Inc.; South San Francisco, CA, USA; 2022."},{"key":"1434_CR75","unstructured":"AbbVie Deutschland GmbH & Co. KG. Venclyxto 10\/50\/100 mg film-coated tablets \u2013 summary of product characteristics. AbbVie Deutschland GmbH & Co. KG; Ludwigshafen, Germany; 2024."},{"key":"1434_CR76","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2020000120","volume":"2020","author":"K Fischer","year":"2020","unstructured":"Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2020;2020:357\u201362.","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01434-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:02:37Z","timestamp":1769536957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01434-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01434-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MSD: Research funding from Ascentage Pharma, MEI Pharma, and Novartis; honoraria from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeOne Medicines Ltd, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Nuvalent, Secura Bio, Takeda Pharmaceuticals, and TG Therapeutics. SS: Honoraria from AbbVie, Acerta Pharma, Amgen, AstraZeneca, BeOne Medicines Ltd, BMS, Celgene, Eli Lilly, F. Hoffmann-La Roche, Gilead Sciences, GSK, Janssen, Novartis, and Sunesis Pharmaceuticals. CST: Research funding from AbbVie, BeOne Medicines Ltd, and Janssen; honoraria from AbbVie, AstraZeneca, BeOne Medicines Ltd, Janssen, and Merck.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}